In this week's EuroBiotech Report, AC Immune lands Lilly deal, AstraZeneca’s tremelimumab fails again and Novo inks diabetes deal.

In our EuroBiotech roundup this week, Affimed eyes accelerated approval, Evox gets Gates funding and ex-Rigontec CEO lands new gig.

The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance.

The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.

UCSF researchers have modified CRISPR gene editing to increase the activity of genes that create the feeling of being full.

Mission Bio will expand its reach into expand its reach into solid tumors and CRISPR applications.

The Harvard researcher who first discovered the "exercise hormone" irisin reports it may be useful in bone formation.

Sunovion and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.

Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its emerging hematology business.

Applied Genetic Technologies’ $1 billion-plus gene therapy pact with Biogen has been torn up after their lead candidate failed a phase 1/2 trial.